WO2022010271A1 - 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도 - Google Patents
보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도 Download PDFInfo
- Publication number
- WO2022010271A1 WO2022010271A1 PCT/KR2021/008681 KR2021008681W WO2022010271A1 WO 2022010271 A1 WO2022010271 A1 WO 2022010271A1 KR 2021008681 W KR2021008681 W KR 2021008681W WO 2022010271 A1 WO2022010271 A1 WO 2022010271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- fusion protein
- vegf
- protein
- crig
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 115
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 115
- 230000024203 complement activation Effects 0.000 title description 20
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 title description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 title description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 title description 2
- 239000003112 inhibitor Substances 0.000 title description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 71
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 69
- 239000012634 fragment Substances 0.000 claims abstract description 50
- 208000030533 eye disease Diseases 0.000 claims abstract description 23
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 239000013636 protein dimer Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 107
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 58
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 39
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 33
- 108091008605 VEGF receptors Proteins 0.000 claims description 32
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 32
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 31
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 31
- 239000013598 vector Substances 0.000 claims description 20
- 239000000539 dimer Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 201000000159 corneal neovascularization Diseases 0.000 claims description 2
- 208000001309 degenerative myopia Diseases 0.000 claims description 2
- 230000004340 degenerative myopia Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 abstract description 19
- 230000037361 pathway Effects 0.000 abstract description 13
- 230000000295 complement effect Effects 0.000 abstract description 12
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 68
- 235000018102 proteins Nutrition 0.000 description 57
- 239000000243 solution Substances 0.000 description 57
- 230000027455 binding Effects 0.000 description 51
- 102100022133 Complement C3 Human genes 0.000 description 42
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 41
- 241000282414 Homo sapiens Species 0.000 description 36
- 241000283973 Oryctolagus cuniculus Species 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 150000001413 amino acids Chemical group 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 230000006698 induction Effects 0.000 description 29
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 22
- 239000007924 injection Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 102000058223 human VEGFA Human genes 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 206010018910 Haemolysis Diseases 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 210000001742 aqueous humor Anatomy 0.000 description 12
- 210000001508 eye Anatomy 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 238000011068 loading method Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 11
- 102100035194 Placenta growth factor Human genes 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 210000004127 vitreous body Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108010081667 aflibercept Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241000282567 Macaca fascicularis Species 0.000 description 9
- 229960002833 aflibercept Drugs 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 8
- 208000008069 Geographic Atrophy Diseases 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 208000022873 Ocular disease Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 108700030335 mouse VSIG4 Proteins 0.000 description 8
- 239000001488 sodium phosphate Substances 0.000 description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 6
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 6
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000046508 human CR1 Human genes 0.000 description 6
- 229940098197 human immunoglobulin g Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012014 optical coherence tomography Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000012515 MabSelect SuRe Substances 0.000 description 5
- 101100328548 Rattus norvegicus C3 gene Proteins 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 241000219198 Brassica Species 0.000 description 4
- 235000003351 Brassica cretica Nutrition 0.000 description 4
- 235000003343 Brassica rupestris Nutrition 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000220259 Raphanus Species 0.000 description 4
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229960002319 barbital Drugs 0.000 description 4
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 4
- 229950000025 brolucizumab Drugs 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000010460 mustard Nutrition 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229960003876 ranibizumab Drugs 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229950000449 vanucizumab Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010048036 Angiopoietin-2 Proteins 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010078015 Complement C3b Proteins 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 102000006834 complement receptors Human genes 0.000 description 3
- 108010047295 complement receptors Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229960002633 ramucirumab Drugs 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011426 transformation method Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000993321 Homo sapiens Complement C2 Proteins 0.000 description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000057840 human FLT4 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- -1 OCT compound Chemical class 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101150016837 VSIG4 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940121431 dilpacimab Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229950005790 navicixizumab Drugs 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- a fusion protein comprising a complement pathway inhibitory protein and an angiogenesis inhibitory protein, and an ophthalmic disease using the same, specifically a composition for treating macular degeneration.
- Macular degeneration refers to a disease characterized by loss of central vision associated with abnormalities of Bruch's membrane, choroid, neural retina and/or retinal pigment epithelium. At the center of the retina is the macula, which is about 1/3 to 1/2 cm in diameter. Below the retina is the choroid, a collection of blood vessels embedded in fibrous tissue, and the pigment epithelium (PE) above the choroid layer. At this time, the choroidal blood vessels provide nutrition to the retina. The choroid and PE are found in the anterior chamber of the eye.
- Age-related macular degeneration is a disease associated with progressive loss of vision in the central part of the visual field, changes in color discrimination, and abnormal cancer adaptation and sensitivity.
- AMD is broadly divided into dry or wet AMD.
- Dry AMD is associated with atrophic cell death in the central retina or macula required for fine vision used for activities such as reading, driving, or facial recognition.
- About 10-20% of the dry AMD patients progress to a type 2 of AMD known as wet AMD.
- drusen an abnormal extracellular deposit behind the retinal pigment epithelium.
- Crystals are the characteristic deposits associated with AMD.
- Such determinants are known to include complement activators, inhibitors, activation-specific complement fragments, and terminal pathway factors such as the cell membrane attack complex (MAC or C5b-9).
- MAC or C5b-9 cell membrane attack complex
- wet AMD is associated with choroidal neovascularization (CNV).
- CNV choroidal neovascularization
- the complement system is a critical component of innate immunity against microbial infection and contains a group of proteins that normally exist in an inactive state in serum.
- the protein is activated through traditional pathways, lectin pathways and alternative pathways. Molecules on the surface of microorganisms can activate this pathway, resulting in the formation of a protease complex known as C3-converting enzyme.
- Activation of the complement pathway involves biologically active fragments of complement proteins that mediate inflammatory responses in leukocyte chemotaxis, activation of macrophages, neutrophils, platelets, mast cells and endothelial cells, increased vascular permeability, cell lysis, and tissue damage, e.g. For example, it produces C3a, and C5a, such as Anaphylatoxins, and C5b-9 Cell Membrane Attack Complex (MAC).
- C3a, and C5a such as Anaphylatoxins, and C5b-9 Cell Membrane Attack Complex (MAC).
- MAC Cell Membrane Attack Complex
- the present inventors completed the present invention by confirming that a fusion protein that blocks the complement-related pathway and the angiogenesis pathway can be utilized as a therapeutic agent for macular degeneration as a result of research to effectively treat and prevent eye diseases, particularly macular degeneration. .
- One aspect of the present invention is a CRIg (Complement receptor of the immunoglobulin superfamily) extracellular domain or a fragment thereof; And it provides a fusion protein comprising a protein that specifically binds to VEGF (Vascular endothelial growth factor).
- CRIg Complement receptor of the immunoglobulin superfamily
- VEGF Vascular endothelial growth factor
- Another aspect of the present invention provides a fusion protein dimer in which the two fusion proteins are bound.
- Another aspect of the present invention provides a polynucleotide encoding the fusion protein.
- Another aspect of the present invention provides a vector comprising the polynucleotide.
- Another aspect of the present invention provides a transformed cell into which the vector is introduced.
- Another aspect of the present invention provides a pharmaceutical composition for the treatment or prevention of eye diseases comprising the fusion protein or fusion protein dimer as an active ingredient.
- Another aspect of the present invention is a CRIg extracellular domain or fragment thereof for treating an ophthalmic disease; And it provides the use of a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- Another aspect of the present invention is a CRIg extracellular domain or fragment thereof for preparing a medicament for the treatment or prevention of eye diseases; And it provides the use of a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- Another aspect of the present invention is an extracellular domain of CRIg or a fragment thereof; And it provides a method for treating and/or preventing an eye disease comprising administering to an individual a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- the fusion protein comprising a protein that specifically binds to VEGF can effectively inhibit complement-related mechanisms as well as angiogenesis. Accordingly, it is possible to effectively treat or prevent ocular diseases induced by the complement system and ocular diseases induced by angiogenesis. Therefore, the fusion protein can be effectively used to effectively treat macular degeneration, in particular, both dry macular degeneration and wet macular degeneration.
- 1 is a view showing the SDS-PAGE results of C1.01, C1.02, C1.03, C1.04, C1.05 and C1.06.
- FIG. 2 is a diagram showing the SDS-PAGE results of C1.03m, C1.04m, and Aflibercept.
- FIG. 3 is a diagram showing the SDS-PAGE results of C1.01m, C1.02m, C1.06m and C1.07m.
- FIG. 4 is a diagram showing SDS-PAGE results of rabbit C3, rabbit C3b, rat C3 and rat C3b.
- FIG. 5 is a diagram showing a schematic diagram of a fusion protein.
- CRIg-Fc C1.01, left
- CRIg-Fc-VEGF binder C1.02, middle
- VEGF binder-Fc-CRIg C1.04, right
- 6A and 6B are graphs showing the binding affinity of C1.01 and C1.02 to human C3b and human VEGF165 by concentration through Biacore analysis.
- 7A and 7B are graphs showing the binding affinity of C1.01m and C1.02m to mouse C3b and human VEGF165 by concentration through Biacore analysis.
- 8A is a graph showing the binding affinity of C1.01, C1.02, C1.03 and C1.04 to human C3b through ELISA.
- 8B is a graph showing the binding affinity of afilibercept, C1.02, C1.04 and C1.05 to human VEGF165 through ELISA.
- 8C is a graph showing the binding affinity for mouse C3b, C1.01, C1.02, and C1.03 binding affinity through ELISA.
- 8D is a graph showing the binding affinity of C1.02 for human C3b, human C2 and human C4 through ELISA.
- 9A is a graph showing the hydrodynamic radius of C1.01 through dynamic light scattering analysis.
- 9B is a graph showing the hydrodynamic radius of C1.02 through dynamic light scattering analysis.
- 11A is a graph showing the inhibitory effect of the alternative complement pathway of C1.01, C1.02 and C1.06 through hemolysis analysis (AH50).
- 11B is a graph showing the alternative complement pathway inhibitory effect of C1.02, C1.04, C1.04m and C1.05 through hemolysis analysis (AH50).
- 11C is a graph showing the alternative complement pathway inhibitory effect of C1.01m, C1.02m, C1.06m and C1.07m through hemolysis analysis (AH50).
- 12A is a graph showing the classical complement pathway inhibitory effect of C1.01, C1.02 and C1.06 through hemolysis analysis (CH50).
- 12B is a graph showing the classical complement pathway inhibitory effect of C1.02, C1.04, C1.04m and C1.05 through hemolysis analysis (CH50).
- 12c is a graph showing the classical complement pathway inhibitory effect of C1.01m, C1.02m, C1.06m and C1.07m through hemolysis analysis (CH50).
- FIG. 13 is a graph showing the VEGF signaling inhibitory effect of afilibercept, C1.01, C1.02, C1.05, and C1.06 using reporter cells.
- FIG. 14 is a graph showing the VEGF signaling pathway inhibitory effect of C1.01, C1.02, and C1.05 through a wound healing assay.
- 15A is a graph showing the binding ability of human and cynomolgus monkey C3b to C1.02 and C3b binding ability of human and cynomolgus monkey to C1.06 through ELISA.
- 15B is a graph showing the binding ability of human, rat and rabbit C3b to C1.02 and C3b binding ability of human, rat and rabbit to C1.06 through ELISA.
- Figure 15c shows the binding capacity of human, cynomolgus monkey, rat and rabbit VEGF to C1.02; And it is a graph showing the binding capacity of human, cynomolgus monkey, rat and rabbit VEGF to C1.01 through ELISA.
- 16A is an image confirming choroidal neovascularization in each experimental group through fluorescein angiography after induction of the choroidal neovascularization mouse model, immediately after induction (Day 0) to 7 days after induction (Day 7).
- 16B is a graph showing the weight of each experimental group after induction of the choroidal neovascularization mouse model, immediately after induction (Day 0), 3 days after induction (Day 3), and 7 days after induction (Day 7).
- Figure 16c is a graph showing the quantification of the degree of choroidal neovascularization for each experimental group immediately after induction (Day 0) to 7 days after induction (Day 7) after induction of the choroidal neovascularization mouse model.
- 17 is a graph showing the quantification of the choroidal neovascularization intensity for each experimental group at 7 days and 14 days after induction of the choroidal neovascularization rabbit model.
- Figure 18a shows the quantification of the presence or absence of choroidal neovascularization in each experimental group immediately after induction and 10 days after induction in the choroidal neovascularization rat model.
- Figure 18b shows the quantification of the extent of vascular leak in each experimental group immediately after induction and 10 days after induction in the choroidal neovascularization rat model.
- FIG. 19 is an image showing the granular layer (ONL) of each experimental group of the dry macular degeneration model ( FIGS. 19a to 19c ), the number of granular cells ( FIG. 19d ), the area of the granular layer ( FIG. 19e ), and the C3 expression level in the retina ( It is a figure which shows FIG. 19f).
- 20A is a graph showing the concentration in the vitreous humor after administration of 2,500 ⁇ g of C1.02 via intraocular injection in rabbits.
- 20B is a graph showing the concentration in the aqueous humor after administration of 2,500 ⁇ g of C1.02 via intraocular injection in rabbits.
- One aspect of the present invention is a CRIg (Complement receptor of the immunoglobulin superfamily) extracellular domain or a fragment thereof; And it provides a fusion protein comprising a protein that specifically binds to VEGF (Vascular endothelial growth factor).
- CRIg Complement receptor of the immunoglobulin superfamily
- VEGF Vascular endothelial growth factor
- CRIg refers to the immunoglobulin complement receptor encoded by the VSIG4 gene, also called Protein Z39Ig.
- the CRIg is a receptor belonging to the type 4 complement receptor among the four types of complement receptors, and is expressed on the surface of macrophages such as Kupffer cells that phagocytose in the liver.
- the CRIg is an Integral Membrane Protein bound to an extracellular region including an immunoglobulin domain.
- CRIg binds to the complement fragments C3b and iC3b, and functions to recognize and eliminate bacteria entering the human body or infectious bacteria in the blood by phagocytic cells.
- the CRIg includes a CRIg isoform or a spliced form.
- the isoform includes CRIg isoform 1, 2 or 3.
- the spliced forms include CRIg(L) or CRIg(S).
- the CRIg(L) may include V and C2-type terminal Ig domains, and CRIg(S) may include only the V-type domain.
- the CRIg(S) may include the sequence of SEQ ID NO: 20.
- the CRIg extracellular domain may be a portion excluding the transmembrane domain and cytoplasmic domain portion of the receptor.
- the CRIg may include a fragment of the CRIg extracellular domain.
- the fragment of the extracellular domain of CRIg means a cleaved form having the same or similar activity to the extracellular domain of CRIg.
- the fragment refers to a fragment of CRIg having an activity of promoting complement action or phagocytosis by binding to C3b or iC3b.
- the CRIg may include the amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 74 or SEQ ID NO: 151.
- human CRIg may have the amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 151
- mouse CRIg may have the amino acid sequence of SEQ ID NO: 21.
- the mouse CRIg extracellular domain may have the amino acid sequence of SEQ ID NO: 75
- the human CRIg extracellular domain may include the amino acid sequence of SEQ ID NO: 22 or SEQ ID NO: 74.
- VEGF Vascular endothelial growth factor
- VEGF Vascular endothelial growth factor
- VEGF is a vascular endothelial growth factor, which is produced by cells that stimulate blood vessel formation.
- VEGF is an important signal transduction protein involved in angiogenesis by dividing and proliferating vascular endothelial cells and increasing vascular permeability.
- the VEGF is known to stimulate abnormal vascular proliferation in the retina in wet AMD.
- VEGF vascular endothelial growth factor
- VEGF-based proteins are collectively referred to as "VEGF”.
- the VEGF-based protein may have an activity equivalent to or similar to that of VEGF.
- activity may refer to, for example, specific binding to a VEGF receptor, and this specific binding may be measured by a method known to those skilled in the art.
- the VEGF-based protein may be one or more selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, Placental growth factor (PlGF) and recombinant VEGF.
- the VEGF may be VEGF-A, B or PlGF.
- the term "PlGF (Placental growth factor)” refers to a transmembrane protein encoded by the 2p21-p16 chromosome.
- the PlGF acts as a ligand selective for VEGFR-1, and may promote angiogenesis.
- the PlGF has at least 40% identity with the amino acid composition of VEGF.
- the PlGF may be PlGF-1 or PlGF-2.
- the term "recombinant VEGF” refers to VEGF recombined through alternative exon splicing.
- the recombinant VEGF may be VEGF111, VEGF121, VEGF145, VEGF148, VEFG165, VEGF183, VEGF189 or VEGF206 depending on the number of amino acids.
- the recombinant VEGF may be VEGF165.
- protein that specifically binds to VEGF refers to an extracellular domain of an antibody or VEGF receptor that specifically binds to VEGF.
- VEGF receptor refers to a receptor that binds to VEGF.
- the VEGF receptor may be any one selected from the group consisting of VEGF receptor 1 (VEGFR-1), VEGF receptor 2 (VEGFR-2), and VEGF receptor 3 (VEGFR-3).
- VEGF receptors contain an immunoglobulin-(Ig)-like domain, an extracellular domain and an intracellularly isolated kinase domain.
- the VEGF receptor is activated by binding to a VEGF ligand, so that dimerization or phosphorylation may occur.
- the VEGF receptor may be VEGF receptor 1 or 2.
- extracellular domain of a VEGF receptor refers to a domain of a VEGF receptor that binds to the VEGF. Specifically, except for the transmembrane region and the cytoplasmic region of the VEGF receptor, it refers to a portion of the extracellular domain including the ligand of VEGF.
- the extracellular domain of the VEGF receptor may be a fragment of the VEGF receptor that binds to VEGF.
- the fragment of the VEGF receptor may include a VEGF receptor domain D1, D2, D3, or a combination thereof, which is a region to which VEGF binds.
- the fragment of the VEGF receptor may include D2 and D3.
- the extracellular domain of the VEGF receptor comprises D2 and D3 domains of VEGF receptor 1 or 2.
- the extracellular domain of the VEGF receptor may bind to VEGF-A, VEGF-B or PlGF to inhibit angiogenesis.
- an embodiment of the extracellular domain of the VEGF receptor may include the amino acid sequence of SEQ ID NO: 14.
- the extracellular domain of the VEGF receptor may be in a form in which a portion of the VEGF receptor extracellular domain comprising SEQ ID NO: 14 is cut or altered.
- antibody that specifically binds to VEGF refers to an antibody or fragment thereof that causes an antigen-antibody reaction by specific binding to VEGF, also referred to as an anti-VEGF antibody.
- the antibody is a generic term for molecules capable of antigen-antibody binding specifically to VEGF.
- the antibody may be used in any form as long as it contains an antigen-binding domain capable of specifically binding to VEGF.
- the antibody or fragment thereof is Fab (Fragment antigen binding), F(ab) 2 , scFv (Single-chain variable fragment), di-scFv, sdAb (Single domain antibody), chimeric antibody, humanized-antibody, human antibody or It may be a variant thereof.
- the anti-VEGF antibody may be a nanobody.
- the antibody may include CDR1 of SEQ ID NO: 49, CDR2 of SEQ ID NO: 50, and CDR3 of SEQ ID NO: 51.
- the antibody may be BI-836880.
- the anti-VEGF antibody is afilibercept, bevacizumab, ranibizumab, ramucirumab, brolucizumab, paricimab, KSI-301, vanu Vanucizumab, BI-836880, HuMab G6-31, B20-4.1, BAT-5906, Navicixizumab, Dilpacimab, hPV-19 and AT-001 selected from the group consisting of It may include any one variable region.
- the anti-VEGF antibody may include a variable region of apilibercept, bevacizumab, ranibizumab, brolucizumab, KSI-301, vanucizumab, BI-836880 or BAT-5906.
- the afilibercept refers to a recombinant humanized fusion protein that inhibits VEGF-A and PlGF in blood vessels.
- the afilibercept may be directly injected into the eye.
- the bevacizumab is an antibody that is an angiogenesis inhibitor that inhibits the growth of blood vessels by inhibiting VEGF-A in blood vessels.
- the bevacizumab can be injected directly into the eye.
- the ranibizumab is a Fab having an effect on the treatment of wet macular degeneration by inhibiting angiogenesis.
- the ramucirumab is a substance mediating angiogenesis or an antibody that inhibits VEGF receptor 2.
- the brolucizumab is an scFv that binds to VEGF-A to inhibit angiogenesis and treats wet macular degeneration.
- the parisimab is a bispecific antibody that inhibits VEGF-A and angiopoietin-2.
- the KSI-301 is an antibody having a therapeutic effect on wet macular degeneration.
- the vanucizumab is a bispecific humanized monochloride antibody that inhibits VEGF-A and angiopoietin-2.
- the BI-836880 is a humanized bispecific nanobody that inhibits VEGF and angiopoietin-2.
- the G6-31 is a Fab fragment that inhibits human VEGF.
- the B20-4.1 is an scFv fragment that inhibits human VEGF.
- the BAT-5906 is an antibody having a therapeutic effect on wet macular degeneration.
- the navicizumab is an anti-DLL4/VEGF bispecific antibody.
- the dilpasimab is an anti-DLL4/VEGF bispecific antibody, also referred to as ABT-165.
- the hPV-19 is an antibody against VEGF with anti-angiogenic and anti-tumor activity.
- the AT-001 is an antibody that inhibits angiogenesis by inhibiting human VEGF receptor 3.
- the anti-VEGF antibody may include a variable region of BI-836880.
- the antibody may include a heavy chain variable region comprising CDR1 of SEQ ID NO: 49, CDR2 of SEQ ID NO: 50 and CDR3 of SEQ ID NO: 51.
- the anti-VEGF antibody may include a variable region of bevacizumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 77, HCDR2 of SEQ ID NO: 78, HCDR3 of SEQ ID NO: 79 and LCDR1 of SEQ ID NO: 80, LCDR2 of SEQ ID NO: 81, LCDR3 of SEQ ID NO: 82 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of ranibizumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 83, HCDR2 of SEQ ID NO: 84, HCDR3 of SEQ ID NO: 85 and LCDR1 of SEQ ID NO: 86, LCDR2 of SEQ ID NO: 87, LCDR3 of SEQ ID NO: 88 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of ramucirumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 89, HCDR2 of SEQ ID NO: 90, HCDR3 of SEQ ID NO: 91 and LCDR1 of SEQ ID NO: 92, LCDR2 of SEQ ID NO: 93, LCDR3 of SEQ ID NO: 94 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of paricizumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 101, HCDR2 of SEQ ID NO: 102, HCDR3 of SEQ ID NO: 103 and LCDR1 of SEQ ID NO: 104, LCDR2 of SEQ ID NO: 105, LCDR3 of SEQ ID NO: 106 It may include a light chain variable region.
- the anti-VEGF antibody may include a KSI-301 variable region.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 108, HCDR3 of SEQ ID NO: 109 and LCDR1 of SEQ ID NO: 110, LCDR2 of SEQ ID NO: 111, LCDR3 of SEQ ID NO: 112 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of vanucizumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 113, HCDR2 of SEQ ID NO: 114, HCDR3 of SEQ ID NO: 115 and LCDR1 of SEQ ID NO: 116, LCDR2 of SEQ ID NO: 117, LCDR3 of SEQ ID NO: 118 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of BAT-5906.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 119, HCDR2 of SEQ ID NO: 120, HCDR3 of SEQ ID NO: 121 and LCDR1 of SEQ ID NO: 122, LCDR2 of SEQ ID NO: 123, LCDR3 of SEQ ID NO: 124 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of navicizumab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 125, HCDR2 of SEQ ID NO: 126, HCDR3 of SEQ ID NO: 127 and LCDR1 of SEQ ID NO: 128, LCDR2 of SEQ ID NO: 129, LCDR3 of SEQ ID NO: 130 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of dilpasimab.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 131, HCDR2 of SEQ ID NO: 132, HCDR3 of SEQ ID NO: 133 and LCDR1 of SEQ ID NO: 134, LCDR2 of SEQ ID NO: 135, LCDR3 of SEQ ID NO: 136 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of hPV-19.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 137, HCDR2 of SEQ ID NO: 138, HCDR3 of SEQ ID NO: 139 and LCDR1 of SEQ ID NO: 140, LCDR2 of SEQ ID NO: 141, LCDR3 of SEQ ID NO: 142 It may include a light chain variable region.
- the anti-VEGF antibody may include a variable region of AT-001.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 143, HCDR2 of SEQ ID NO: 144, HCDR3 of SEQ ID NO: 145 and LCDR1 of SEQ ID NO: 146, LCDR2 of SEQ ID NO: 147, LCDR3 of SEQ ID NO: 148 It may include a light chain variable region.
- the anti-VEGF antibody comprises a heavy chain of SEQ ID NO: 36 and a light chain of SEQ ID NO: 37; a heavy chain of SEQ ID NO: 38 and a light chain of SEQ ID NO: 39; a heavy chain of SEQ ID NO: 40 and a light chain of SEQ ID NO: 41; a heavy chain of SEQ ID NO: 43 and a light chain of SEQ ID NO: 44; a heavy chain of SEQ ID NO: 45 and a light chain of SEQ ID NO: 46; a heavy chain of SEQ ID NO: 47 and a light chain of SEQ ID NO: 48; a heavy chain of SEQ ID NO: 64 and a light chain of SEQ ID NO: 65; a heavy chain of SEQ ID NO: 66 and a light chain of SEQ ID NO: 67; a heavy chain of SEQ ID NO: 68 and a light chain of SEQ ID NO: 69; a heavy chain variable region of SEQ ID NO: 70 and a light chain variable region of SEQ ID NO: 70
- the fragment of the anti-VEGF antibody may be a single chain variable fragment (scFv).
- the scFv refers to a form in which the heavy chain variable region and the light chain variable region are linked by a peptide linker.
- the scFv may include a variable region comprising CDR1 of SEQ ID NO: 95, CDR2 of SEQ ID NO: 96, CDR3 of SEQ ID NO: 97, CDR4 of SEQ ID NO: 98, CDR5 of SEQ ID NO: 99 and LCDR6 of SEQ ID NO: 100 have.
- the scFv may have the amino acid sequence of SEQ ID NO: 42.
- one embodiment of the scFv may be brolucizumab.
- the anti-VEGF antibody may include a variable region of HuMab G6-31 or B20-4.1.
- the antibody comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 52, HCDR2 of SEQ ID NO: 53, HCDR3 of SEQ ID NO: 54 and LCDR1 of SEQ ID NO: 55, LCDR2 of SEQ ID NO: 56, LCDR3 of SEQ ID NO: 57 It may include a light chain variable region.
- the antibody is a heavy chain variable region comprising HCDR1 of SEQ ID NO: 58, HCDR2 of SEQ ID NO: 59, HCDR3 of SEQ ID NO: 60 and a light chain comprising LCDR1 of SEQ ID NO: 61, LCDR2 of SEQ ID NO: 62, LCDR3 of SEQ ID NO: 63 It may include a variable region.
- the antibody that specifically binds to VEGF may refer to an antibody known to those skilled in the art without limitation.
- the antibody may be an anti-VEGF antibody or fragment thereof disclosed in US Patent No. 9,527,925 B2, US Patent No. 8,268,314 B2, or US Patent Publication No. US 2019-0167790 A1.
- the protein that specifically binds to the extracellular domain of CRIg or a fragment thereof and VEGF may be bound through a linker.
- the extracellular domain of CRIg or a fragment thereof and an immunoglobulin fragment may be linked through a linker.
- the linker connects two proteins.
- One embodiment of the linker may include 1 to 50 amino acids, albumin or a fragment thereof, or an Fc domain of an immunoglobulin.
- the Fc domain of the immunoglobulin includes the heavy chain constant region 2 (CH2) and the heavy chain constant region 3 (CH3) of the immunoglobulin, and includes the variable regions and the light chain constant region 1 (CH1) of the heavy and light chains of the immunoglobulin protein that does not
- the immunoglobulin may be IgG, IgA, IgE, IgD or IgM, preferably IgG1.
- the Fc domain may refer to a region including the CH2 and CH3 domains, except for the hinge region.
- fusion protein may be of the following structural formula (I) or (II):
- the N' is the N-terminus of the fusion protein
- X is an extracellular domain of CRIg or a fragment thereof
- Y is a protein that specifically binds to VEGF
- linker (1) and linker (2) are peptide linkers
- n and m are each independently O or 1.
- the protein that specifically binds to VEGF, the extracellular domain of the CRIg or a fragment thereof, and the Fc domain are as described above.
- the Fc domain may include the CH2 and CH3 regions of an immunoglobulin Fc heavy chain.
- the Fc domain of the immunoglobulin may be a wild-type Fc domain as well as an Fc domain variant.
- the term "Fc domain variant" as used herein is different from the glycosylation pattern of the wild-type Fc domain, increased sugar chains compared to the wild-type Fc domain, reduced sugar chains compared to the wild-type Fc domain, or the sugar chains are removed ( It may be in a deglycosylated form. It also includes an Aglycosylated Fc domain.
- the Fc domain or variant may have a number of sialic acid, fucosylation, and glycosylation adjusted through culture conditions or host genetic manipulation.
- the sugar chain of the Fc domain of an immunoglobulin can be modified by a conventional method such as a chemical method, an enzymatic method, and a genetic engineering method using microorganisms.
- the Fc domain variant may be a mixed form of immunoglobulin IgG, IgA, IgE, IgD or IgM Fc region.
- the Fc domain variant may be a form in which some amino acids of the Fc domain are substituted with other amino acids.
- Fc domain variant refers to an Fc domain in which the sugar chain of the wild-type Fc domain is altered, a sequence between Fc domains is mixed, or some amino acids of the wild-type Fc domain are deleted, altered, substituted and/or added. do. Deletion, alteration, substitution and/or addition of some amino acids of the wild-type Fc domain may be prepared by methods known to those skilled in the art. In one embodiment, the Fc domain variant may be one in which some amino acid sequences of the wild-type Fc domain are substituted and/or added.
- amino acid introduced by the above substitution and/or addition is lysine (K), alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glutamine (Q). ), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T) ), tryptophan (W), tyrosine (Y), and may be any one selected from the group consisting of valine (V).
- V valine
- the Fc domain mutation may be to modulate the activity or function of the antibody. In one embodiment, the Fc domain mutation may be to modulate an effector function or antibody cytotoxic activities of an antibody.
- the Fc domain variant may include a DANG mutation or a NG mutation.
- the Fc domain variant may be an IgG1 Fc domain in which the 265th sequence is substituted with D to A, the 297th sequence is substituted with N to G, or a combination thereof.
- the Fc domain may have any one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 11, and SEQ ID NO: 76.
- the Fc domain may be encoded by the polynucleotide sequence of SEQ ID NO: 28 or SEQ ID NO: 33.
- the peptide linker (1) may consist of 5 to 80 consecutive amino acids, 20 to 60 consecutive amino acids, or 25 to 50 consecutive amino acids, or 30 to 40 amino acids. In one embodiment, the peptide linker (1) may consist of 30 amino acids. In addition, the peptide linker (1) may include at least one cysteine. Specifically, it may contain one, two or three cysteines. In addition, the peptide linker (1) may be derived from the hinge of an immunoglobulin. In one embodiment, the peptide linker (1) may be a peptide linker consisting of the amino acid sequence of SEQ ID NO: 15 or 17.
- the peptide linker (2) may consist of 1 to 50 consecutive amino acids, or 3 to 30 consecutive amino acids, or 5 to 15 amino acids.
- the peptide linker (2) may be (G4S)n (in this case, n is an integer of 1 to 10). In this case, in (G4S)n, n may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- the peptide linker (2) may be a peptide linker consisting of the amino acid sequence of SEQ ID NO: 16 or 18.
- the fusion protein may be of structural formula (I).
- the fusion protein may include any one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 8, and SEQ ID NO: 10.
- the fusion protein is 85%, 86%, 87%, 88% of any one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 10; 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
- identity for example, percent homology, may be determined through homology comparison software such as BlastN software of the National Center of Biotechnology Information (NCBI).
- Another aspect of the present invention provides a dimer to which two fusion proteins comprising the extracellular domain of CRIg or a fragment thereof and a protein specifically binding to VEGF are bound.
- the bond between the fusion proteins constituting the dimer may be formed by a disulfide bond by a cysteine present in the linker, but is not limited thereto.
- the fusion proteins constituting the dimer may be the same, but may be different fusion proteins.
- the dimer may be a homodimer.
- Another aspect of the present invention provides a polynucleotide encoding a fusion protein comprising the extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.
- the polypeptide is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86% SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 8, or SEQ ID NO: 10 , at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96% , an amino acid sequence having at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity.
- the polynucleotide is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity.
- the polynucleotide may additionally include a nucleic acid encoding a signal sequence or a leader sequence.
- signal sequence refers to a signal peptide that directs secretion of a target protein.
- the signal peptide is cleaved after translation in the host cell.
- the signal sequence is an amino acid sequence that initiates the movement of the protein through the ER (Endoplasmic reticulum) membrane.
- the signal sequence is well-known in the art, and typically includes 16 to 30 amino acid residues, but may include more or fewer amino acid residues than that.
- a typical signal peptide consists of three regions: a basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region.
- the central hydrophobic region contains 4 to 12 hydrophobic residues that anchor the signal sequence through the membrane lipid bilayer during migration of the immature polypeptide.
- the signal sequence is cleaved in the lumen of the ER by cellular enzymes commonly known as signal peptidases.
- the signal sequence may be a secretion signal sequence of tPa (Tissue Plasminogen Activation), HSV gDs (Signal sequence of Herpes simplex virus glycoprotein D), or growth hormone.
- tPa tissue Plasminogen Activation
- HSV gDs Synignal sequence of Herpes simplex virus glycoprotein D
- growth hormone a secretion signal sequence used in higher eukaryotic cells, including mammals, may be used.
- the signal sequence may be used by using a wild-type signal sequence or by substituting a codon having a high expression frequency in a host cell.
- Another aspect of the present invention provides a vector comprising the polynucleotide.
- the vector can be introduced into a host cell, recombination and insertion into the host cell genome. or said vector is understood as a nucleic acid means comprising a polynucleotide sequence capable of spontaneous replication as an episome.
- Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors and analogs thereof.
- examples of viral vectors include, but are not limited to, retroviruses, adenoviruses, and adeno-associated viruses.
- the vector may be plasmid DNA, phage DNA, etc., commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), E. coli-derived plasmids (pYG601BR322, pBR325, pUC118, pUC119, etc.), Bacillus subtilis plasmids (pUB110, pTP5, etc.), yeast-derived plasmids (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, ⁇ gt10, ⁇ gt11, ⁇ ZAP, etc.), animal virus vectors (retroviruses) ), adenovirus, vaccinia virus, etc.), insect virus vectors (baculovirus, etc.). Since the vector exhibits different protein expression levels and modifications depending on the host cell, it is preferable to select and use a host cell most suitable
- the term "gene expression” or "expression” of a protein of interest is understood to mean transcription of a DNA sequence, translation of an mRNA transcript, and secretion of a fusion protein product or fragment thereof.
- a useful expression vector may be RcCMV (Invitrogen, Carlsbad) or a variant thereof.
- the expression vector includes a human CMV (Cytomegalovirus) promoter to promote continuous transcription of a target gene in mammalian cells, and a bovine growth hormone polyadenylation signal sequence to increase the stable-state level of RNA after transcription. can do.
- Another aspect of the present invention provides a transformed cell into which the vector is introduced.
- the host cell of the transformed cell may include, but is not limited to, a cell of prokaryotic, eukaryotic, mammalian, plant, insect, fungal or cellular origin.
- a cell of prokaryotic, eukaryotic, mammalian, plant, insect, fungal or cellular origin As an example of the prokaryotic cell, E. coli may be used. In addition, yeast may be used as an example of eukaryotic cells.
- CHO cells, F2N cells, CSO cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, HEK 293 cells or HEK293T cells may be used as the mammalian cells. , but is not limited thereto, and any cell that can be used as a mammalian host cell known to those skilled in the art is available.
- the CaCl 2 precipitation method when introducing the expression vector into a host cell, the CaCl 2 precipitation method, the CaCl 2 precipitation method using a reducing material called DMSO (dimethyl sulfoxide), which increases the efficiency by using the Hanahan method, the electroporation method, the calcium phosphate precipitation method , protoplast fusion method, agitation method using silicon carbide fiber, agrobacterium mediated transformation method, transformation method using PEG, dextran sulfate, lipofectamine and drying/inhibition mediated transformation method, etc.
- DMSO dimethyl sulfoxide
- the glycosylation-related gene possessed by the host cell is manipulated through a method known to those skilled in the art, and the sugar chain pattern of the fusion protein (e.g., sialic acid, fucosylation, glycation) can be adjusted.
- the sugar chain pattern of the fusion protein e.g., sialic acid, fucosylation, glycation
- the extracellular domain of CRIg or a fragment thereof comprising the step of culturing the transformed cells; And it provides a method for producing a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- the production method comprises the steps of i) culturing the transformed cells to obtain a culture; and ii) recovering the fusion protein or a dimer thereof from the culture.
- the method of culturing the transformed cells can be performed using a method well known in the art. Specifically, the culture may be continuously cultured in a batch process or in a fed batch or repeated fed batch process (Fed batch or Repeated fed batch process).
- Another aspect of the present invention provides a pharmaceutical composition for the treatment or prevention of eye diseases comprising the fusion protein or a fusion protein dimer to which two fusion proteins are bound as an active ingredient.
- the fusion protein and the fusion protein dimer are as described above.
- eye disease may refer to diseases in which the eye is the site of disease.
- the ocular disease may refer to an ocular disease triggered or aggravated by complement activity or angiogenesis or an ocular disease including excessive angiogenesis as a major condition.
- the eye diseases include age-related macular degeneration (AMD), map atrophy (GA), choroidal neovascularization (CNV), uveitis, diabetic and other ischemia-related retinopathy, diabetic macular edema, pathological myopia, von Hippel- It may be any one selected from the group consisting of Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), corneal neovascularization, and retinal neovascularization.
- AMD age-related macular degeneration
- GA map atrophy
- CNV choroidal neovascularization
- uveitis diabetic and other ischemia-related retinopathy
- diabetic macular edema diabetic macular edema
- pathological myopia von Hippel- It may be any one selected from the group consisting of Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), corneal neovascularization,
- Proteins specifically binding to the extracellular domain of CRIg or fragments thereof and VEGF are as described above.
- the preferred dosage of the pharmaceutical composition varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route and duration of administration, but may be appropriately selected by those skilled in the art.
- the active ingredient may exhibit ocular disease therapeutic activity, or, in particular, any amount ( effective amount), a typical effective amount will be determined within the range of 0.001% to 20.0% by weight based on the total weight of the composition.
- the term "effective amount" refers to an amount of an active ingredient capable of inducing an improvement or treatment effect of an eye disease, particularly an improvement or therapeutic effect of macular degeneration. Such an effective amount can be determined empirically within the ordinary ability of one of ordinary skill in the art.
- treatment may be used to include both therapeutic treatment and prophylactic treatment. In this case, prevention may be used in the sense of alleviating or reducing a pathological condition or disease of an individual.
- treatment includes any form of administration or application for treating a disease in a mammal, including a human. The term also includes inhibiting or slowing the disease or its progression; restoring or repairing damaged or missing function, thereby partially or completely alleviating the disease; or stimulate inefficient processes; It includes the meaning of alleviating serious diseases.
- “enhanced efficacy” eg, improvement in efficacy
- improved efficacy can be attributed to improved pharmacokinetic parameters and improved efficacy, as determined by comparing parameters such as clearance rate and treatment or improvement of ophthalmic diseases in a test animal or human subject.
- the term "therapeutically effective amount” or “pharmaceutically effective amount” refers to an amount of a compound or composition effective to prevent or treat a target disease, and treat the disease at a reasonable benefit/risk ratio applicable to medical treatment. It means an amount that is sufficient and does not cause side effects.
- the level of the effective amount may be determined by the patient's health condition, disease type, severity, drug activity, drug sensitivity, administration method, administration time, administration route and excretion rate, treatment period, factors including the combination or concurrently used drugs; It may be determined according to factors well known in the medical field.
- a therapeutically effective amount refers to an amount of a drug effective to treat an ocular disease.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be any non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fats, waxes and inert solids may be included as carriers. Pharmaceutically acceptable adjuvants (buffers, dispersants) may also be included in the pharmaceutical composition.
- the pharmaceutical composition may be prepared as a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient.
- pharmaceutically acceptable means that it does not inhibit the activity of the active ingredient and does not have toxicity beyond what the application (prescription) target can adapt.
- the pharmaceutical composition When the pharmaceutical composition is prepared for parenteral use, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories together with suitable carriers according to methods known in the art.
- suitable carriers preferably Ringer's solution, PBS (Phosphate Buffered Saline) containing triethanolamine or sterile for injection Water, an isotonic solution such as 5% dextrose, etc. may be used.
- PBS Phosphate Buffered Saline
- an isotonic solution such as 5% dextrose, etc.
- a preferred dosage of the pharmaceutical composition is in the range of 0.01 ug/kg to 10 g/kg, or 0.01 mg/kg to 1 g/kg per day, depending on the patient's condition, weight, sex, age, patient's severity, and administration route. can be Administration may be performed once or divided into several times a day. Such dosages should not be construed as limiting the scope of the present invention in any respect.
- Subjects to which the pharmaceutical composition can be applied are mammals and humans, particularly preferably humans.
- the pharmaceutical composition of the present application may further include any compound or natural extract known to have an effect on treating eye diseases, particularly macular degeneration.
- the extracellular domain of CRIg or a fragment thereof for treating an ophthalmic disease provides the use of a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- the extracellular domain of CRIg or a fragment thereof for preparing a medicament for the treatment or prevention of eye diseases provides the use of a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- the extracellular domain of CRIg or a fragment thereof provides a method for treating and/or preventing an eye disease comprising administering to an individual a fusion protein or a dimer thereof comprising a protein that specifically binds to VEGF.
- the fusion protein, the dimer and the eye disease are as described above.
- the subject may be an individual suffering from an eye disease.
- the subject may be a mammal, preferably a human.
- the administration route, dosage, and frequency of administration of the fusion protein or fusion protein dimer may be administered to a subject in various ways and amounts depending on the patient's condition and side effects, and the optimal administration method, dosage and frequency of administration are A person skilled in the art can select within an appropriate range.
- the fusion protein or fusion protein dimer may be administered in combination with other drugs or physiologically active substances with known therapeutic effects for the disease to be treated, or formulated in the form of a combination preparation with other drugs.
- the fusion protein may inhibit the complement pathway, phagocytosis and/or angiogenesis. Therefore, it can be effectively used for eye diseases such as wet or dry macular degeneration.
- eye diseases such as wet or dry macular degeneration.
- the extracellular domain of CRIg or a fragment thereof and it was confirmed that the case of combining a protein that specifically binds to VEGF has a higher effect and a synergistic effect than when including one. Therefore, the fusion protein can effectively treat dry and wet macular degeneration by effectively inhibiting the complement pathway and angiogenesis.
- C1.01 (SEQ ID NO: 1) consists of human IgG1 Fc from which the effector function has been removed through the extracellular domain region (20-283), linker, and DANG mutations (D265A, N297G) of human CRIg protein.
- C1.02 (SEQ ID NO: 2) consists of an extracellular domain region (20-283) of human CRIg protein, a linker and human IgG1 Fc DANG, a linker, and a VEGF binding site of Aflibercept.
- C1.03 (SEQ ID NO: 3) consists of human IgG1 Fc DANG, a linker and the extracellular domain region (20-283) of human CRIg protein.
- C1.04 (SEQ ID NO: 4) is composed of the VEGF binding site of apilibercept and the linker, human IgG1 Fc DANG, the linker and the extracellular domain region (20-283) of the human CRIg protein.
- C1.05 (SEQ ID NO: 5) is composed of the VEGF binding site of afilibercept, a linker and human IgG 1 Fc DANG.
- C1.06 (SEQ ID NO: 6) consists of human IgG 1 Fc DANG.
- C1.01m (SEQ ID NO: 7) is composed of mouse IgG2a Fc in which the effector function is removed through the extracellular domain region (20 to 187), linker and DANG mutations (D265A, N297G) of the mouse CRIg protein.
- C1.02m (SEQ ID NO: 8) consists of the extracellular domain region (20 to 187) of the mouse CRIg protein, a linker, a mouse IgG2a Fc DANG, a linker, and a VEGF binding site of Aflibercept.
- C1.03m (SEQ ID NO: 9) consists of a mouse IgG2a Fc DANG, a linker and an extracellular domain region (20-187) of the mouse CRIg protein.
- C1.04m (SEQ ID NO: 10) is composed of the VEGF binding site of apilibercept and the linker, mouse IgG2a Fc DANG, the linker and the extracellular domain region (20 to 187) of the mouse CRIg protein.
- C1.06m (SEQ ID NO: 11) consists of mouse IgG2a Fc DANG.
- C1.07m (SEQ ID NO: 12) is mouse IgG2a It consists of Fc DANG, a linker and the VEGF binding site of afilibercept.
- Tables 2 and 3 below describe the reagents and equipment used.
- the synthesized DNA fragment was amplified through PCR, and the PCR product was purified with a gel. After cutting the pTT5 vector with restriction enzymes EcoRI and BamHI, the gel was purified. Each PCR product and the linear vector were ligated using the In-Fusion Kit. The resulting vector was transformed into ECOS101 DH5 ⁇ competent cells and cultured on 2xYT agar plates containing 100 ⁇ g/ml ampicillin. All manipulations were performed according to standard transformation protocols. Positive recombinants were confirmed by colony PCR, and sequence-verify sequencing was performed on the recombinant plasmid. A single colony was selected and the seed culture was inoculated into 5 mL 2 x YT medium containing 100 ⁇ g/ml ampicillin. Incubated with shaking at 37°C for 8 hours.
- the seed cells were diluted in 200 mL of selective 2 x YT medium at a ratio of 1:1,000. Incubated with shaking at 37°C for 16 hours. Bacterial cells were harvested by centrifugation at 4,700 rpm at 4°C for 10 minutes. Resuspend the bacterial pellet in 12 mL of RES-EF solution. Then, 12 mL of LYS-EF solution was added, and the sealed tube was vigorously inverted to thoroughly mix, and then incubated for 5 minutes at room temperature. 12 mL of NEU-EF solution was added to the lysate and inverted vigorously to mix thoroughly.
- a homogeneous suspension of the precipitate was prepared by inverting the lysate tube 3 times to prevent clogging of the filter. Then, the NucleoBond® Xtra column filter and the NucleoBond® Xtra column were washed with 10 mL of filter washing solution FIL-EF. Remove the NucleoBond® Xtra column filter by pulling out or inverting the column. Wash the NucleoBond® Xtra column with 90 mL of wash solution ENDO.
- the NucleoBond® Xtra column was washed with 45 mL of wash solution WASH-EF. Plasmid DNA was eluted with 15 mL of elution solution ELU. The eluate was collected in a 50 mL centrifuge tube. 10.5 mL of room temperature isopropanol was added to precipitate the eluted plasmid DNA. After vortexing, the mixture was left standing for 2 minutes.
- 293F seed strain containing complete medium was maintained in an incubator shaker at 130 rpm, 37°C and 8% CO 2 .
- Cells were cultured at a density of 0.3 to 0.4x10 6 cells/ml, and the medium was changed every 2 to 3 days.
- 24 hours before transfection freshly passaged 293F cells were prepared at 2.6x10 6 cells/ml.
- the prepared cells were cultured in an incubator shaker at 130 rpm, 37° C. and 8% CO 2 .
- On the day of transfection cells were adjusted to a density of 5.0x10 6 cells/ml using fresh medium. A total volume of 1 L was performed in a 3 L shaker flask.
- HC and 0.6 mg LC plasmids were diluted with 50 ml OPTI MEM I and filtered through a 0.22 ⁇ m filter. Then, 2 mg PEI was diluted with 50 mL OPTI MEM I to prepare transfection reagent.
- Diluted PEI was added to the DNA mixture and mixed immediately. Then, incubated at room temperature for 15 minutes.
- a DNA-PEI mixture was added to 293F cells prepared at 2.6x10 6 cells/ml. Thereafter, the cells were cultured continuously for 24 hours in an incubator shaker at 130 rpm, 37° C. and 8% CO 2 . 24 hours after transfection, 10% peptone was added to 1/20 of the culture solution to a final concentration of 0.5%. Thereafter, the cells were continuously cultured in an incubator shaker at 130 rpm, 37° C. and 8% CO 2 . Cell density/viability was measured and recorded daily in the 2-5 day period post-transfection. Cells were harvested for purification 7 days after transfection or when cell viability was less than 70%.
- Tables 5 to 7 below show the reagents used for protein purification, the composition of each solution, and equipment.
- Proteins were purified using a Mabselect sure column. Specifically, the supernatant was harvested by centrifugation at 2,000xg and 4°C for 20 minutes. Then, the supernatant was filtered through a Sartopore 2 filter. The clarified supernatant was loaded onto a 5 ml MabSelect Sure column equilibrated with solution A. After that, the column was washed with solution A until the A280 absorbance reached the baseline. The column was washed with 10 CV solution B. The column was washed with 10 CV solution A. The bound protein was eluted with 6 CV solution C, 1/6 volume of solution D was added to neutralize the eluted material, and SDS-PAGE and SEC-HPLC analysis were performed.
- the protein was purified through a HIC column.
- the protein was then dialyzed against solution E at 4° C. overnight.
- the supernatant was loaded onto a HIC column equilibrated with solution E.
- the column was washed with solution E until the A280 absorbance reached a baseline value.
- the bound protein was eluted by gradient elution (10 CV solution F 0%-40%).
- the bound protein was eluted with 2 CV 100% solution F, and SDS-PAGE analysis was performed.
- the proteins were collected in one place, and then the protein was dialyzed against the final solution at 4°C overnight. Then, SDS-PAGE and SEC-HPLC analysis were performed.
- a DNA fragment corresponding to the protein sequence was synthesized in Genewiz (No. 80-383034849).
- the corresponding DNA fragment was amplified by PCR and introduced using the linearized pcDNA3.3 expression vector. After verifying the structure through sequencing, a sufficient amount of DNA was obtained to perform cell transfection through a large-scale plasmid manufacturing process.
- Plasmid DNA and ExpiFectamine TM 293 reagent were first diluted in Opti-MEM, mixed and added to the cell culture medium.
- Cell culture was performed on a platform shaker at a stirring speed of 150 rpm. The temperature was maintained at 37° C. and the CO 2 concentration was 8%. After 18 to 20 hours after transfection, enhancer 1 and enhancer 2 were added to the cell culture medium.
- ThermoFisher After 6 days of cell culture, the cells were centrifuged at 4,000 rpm at 25° C. for 10 minutes. The supernatant was collected for purification and gel electrophoresis. The supernatant was loaded onto an SDS-PAGE gel according to the instructions for NuPAGETM 4-12% Bis-Tris Protein Gels (ThermoFisher). A PageRuler TM Unstained Protein Ladder (ThermoFisher) was used together with the protein sample to measure the molecular weight of the protein. The remaining supernatant of each protein was used for subsequent purification.
- Protein purification was performed as follows. Specifically, the Protein A column (Protein A column) was prepackaged with MabSelect Sure resin. Before loading the cell culture, the column was equilibrated with 0.1 M Tris, pH 7.0. After loading the cell culture medium, the column was washed with 0.1 M Tris, pH 7.0, and then eluted with 0.1 M glycine, pH 3.5. The eluted material was neutralized by adding 0.1 M Tris, pH 9.0. Then, the sample was dialyzed in PBS solution (Sangon Biotech, B548117-0500).
- the SEC column Prior to sample loading, the SEC column (GE lifesciences, Superdex 200 increase 10/300) was equilibrated with PBS. After loading, samples were eluted with PBS and collected by chromatography. SDS-PAGE was performed to analyze each peak. Each sample was dialyzed against a formulation solution (10 mM Sodium phosphate, 0.3 to 0.4 M NaCl, pH 6.8).
- the CHT column was prepackaged with CHT resin (Bio-rad, MPC TM Ceramic Hydroxyfluoroapatite), and equilibrated with solution A (10 mM sodium phosphate, 30 mM NaCl, pH 6.8) before loading the sample. After loading, the column was eluted with 30% solution B (10 mM Sodium phosphate, 1 M NaCl, pH 6.8), followed by a linear gradient of 30% to 90% solution B and a final 100% solution B. The eluate was characterized by SDS-PAGE, and the sample was dialyzed against a formulation solution (10 mM Sodium phosphate, 0.3 to 0.4 M NaCl, pH 6.8). The final protein was filtered through a 0.2 ⁇ m filter, and aseptically dispensed in an amount of 0.5 mL into 1.5 mL tubes.
- CHT resin Bio-rad, MPC TM Ceramic Hydroxyfluoroapatite
- the concentration of the protein was measured at 280 nm using a nano drop.
- the purity of the protein was confirmed by SDS-PAGE and HPLC-SEC.
- SDS-PAGE samples were prepared by mixing 15 ⁇ L of purified protein and 5 ⁇ L of 4x loading buffer, and boiling for 5 minutes. 15 ⁇ L of the mixed sample was loaded on NuPAGE Bis-Tris Mini Gels 4 to 12% gel. In order to proceed with SEC-HPLC analysis, 80 ⁇ L of purified protein was loaded on a TSKgel G3000SWxl column of HPLC system 1260 Infinity II, pH 7.0, 50 mM sodium phosphate, 150 mM sodium chloride was used as a running buffer.
- Tables 9 to 11 below show the composition and equipment of reagents and solutions used for C3 purification of rabbits and rats.
- DEAE column solution A 10 mM Potassium phosphate (KH 2 PO 4 ), 5 mM ethylenediaminetetraacetic acid disodium salt (EDTA), 1 mM benzamidine, pH 7.8 solution B 10 mM Potassium phosphate (KH 2 PO 4 ), 5 mM EDTA, 1 mM benzamidine, 1 M sodium chloride (NaCl), pH 7.8 MonoS column solution A 50 mM Sodium phosphate (NaH 2 PO 4 ) solution B 50 mM Sodium phosphate (NaH 2 PO 4 ), 1 M sodium chloride (NaCl), pH 5.5 S200 column solution Phosphate-buffered saline (PBS), pH 7.4
- the volume, A280, and conductivity of the dialysate were checked. If the solution was turbid or precipitated, the precipitate was removed by centrifugation at 4,000xg, 4°C for 15 minutes. The dialysate was filtered through a 0.2 ⁇ m filter and stored on ice until purification.
- Protein purification was performed in the order of anion exchange chromatography, cation exchange chromatography, and size exclusion chromatography.
- the DEAE column (GE healthcare, HiPrep TM DEAE Fast Flow 16/10) was equilibrated with solution A (10 mM KH 2 PO 4 , 5 mM EDTA, 1 mM benzamidine, pH 7.8).
- solution A 10 mM KH 2 PO 4 , 5 mM EDTA, 1 mM benzamidine, pH 7.8
- the column was washed with solution A and eluted with a 0-50% linear gradient solution B (10 mM KH 2 PO 4 , 5 mM EDTA, 1 mM benzamidine, 1 M NaCl, pH 7.8).
- the compartments of the eluate were analyzed through SDS-PAGE, and A280 was identified by collecting the compartments including C3.
- the obtained eluate was dialyzed in 2L Mono S solution A (50 mM Sodium phosphate) at 4°C for 2 hours.
- the Mono S column (GE healthcare, Mono S ® 5/50 GL) was equilibrated with solution A (50 mM sodium phosphate) before loading the dialysate. After DEAE eluent loading, the column was washed with solution A and eluted with 0-35% linear gradient solution B (50 mM Sodium phosphate, 1 M NaCl, pH 5.5). Partitions of the eluate were analyzed through SDS-PAGE, and A280 was identified by collecting the peak partitions located in the center.
- the SEC column Prior to sample loading, the SEC column (GE lifesciences, Superdex 200 increase 10/300) was equilibrated with PBS. After loading, samples were eluted with PBS and collected by chromatography. SDS-PAGE was performed to analyze each peak. A280 was confirmed by collecting the peak C3 compartments located in the center.
- C3 was prepared by diluting 0.5 mg/mL of PBS. C3 was converted to C3b by adding 0.4 ⁇ M factor B, 0.05 ⁇ M factor D and 5 mM MgCl 2 , and incubating at 25° C. for 30 minutes. C3b was further purified through a Superdex 200 (60 mL) gel filtration column. Next, SDS-PAGE and SEC-HPLC analysis of rabbit C3, rabbit C3b, rat C3 and rat C3b were performed.
- Table 12 shows the materials and reagents used.
- 1 L 1x HBS-EP+ buffer was prepared by mixing 100 mL 10x HBS-EP+ buffer with 900 mL Milli-Q water. After mixing 50 mM NHS and 200 mM EDC in a 1:1 ratio for 420 seconds, the CM5 chip was activated at a flow rate of 10 uL/min. To reach a fixation level of about 10,000 RU, 25 ug/mL of anti-human immunoglobulin G(Fc) antibody (pH 5.0 acetate) was injected at a rate of 10 uL/ml for 400 seconds. The remaining activated ester groups were blocked by injecting 1 M ethanolamine (pH 8.5) at a rate of 10 uL/min for 420 seconds. To stabilize the baseline, the sensor chip was washed with 1xHBS-EP+ at a rate of 10 uL/min for 16 hours.
- a startup cycle consisting of a sample step and a regeneration step was performed three times for baseline stabilization.
- Sample step: 1x HBS-EP+ buffer was injected into the flow cell at a flow rate of 30 uL/min for 120 seconds, followed by a cleavage phase for 120 seconds and a stabilization phase for 30 seconds.
- Regeneration step: 10 mM glycine pH 1.5 was injected into the flow cell at a rate of 30 uL/min for 30 seconds, followed by a stabilization step of 30 seconds.
- C3b stock solution was diluted to 50 nM using 1x HBS-EP+ buffer.
- Human VEGF165 was diluted to 5 nM using 1x HBS-EP+ buffer.
- the 50 nM and 5 nM solutions were then diluted to 0.78125 nM and 0.078125 nM.
- the diluted antigens were injected into the flow cell at a rate of 30 uL/min.
- Two 0 nM antigens (1x HBS-EP+ buffer) were used to remove the reference signal. Bind for 180 seconds and separated for 400 seconds. After the separation time, a stabilization step for 60 seconds was performed.
- 10 mM pH 1.5 glycine (Glycine) was injected into the flow cells at a rate of 30 uL/min for 30 seconds, followed by a stabilization step for 60 seconds.
- binding kinetics were calculated using Biacore Insight Evaluation Software (Version 2.0.15.12933) and 1:1 binding model for curved fitting.
- Table 13 below shows the binding affinities of the test substances.
- human C3b protein was immobilized on a plate and bound to C1.01, C1.02, C1.03, C1.04, and hIgG1 as a control.
- an anti-human immunoglobulin G antibody and an anti mustard radish peroxidase (HRP) antibody were sequentially coupled.
- mouse C3b protein was immobilized on a plate, and C1.01m to C1.03m containing mouse CRIg were bound to mouse C3b.
- FIG. 8A it was confirmed that C1.01, C1.02, C1.03 and C1.04 containing CRIg bind to human C3b in a concentration dependent manner.
- FIG. 8c it was confirmed that C1.01m to C1.03m containing mouse CRIg also bind to mouse C3b in a concentration-dependent manner.
- the binding of the fusion protein and human VEGF165 protein to human VEGF165 was determined through enzyme immunoassay, afilibercept, C1.02, C1.04 and C1.05. of the binding affinity was confirmed through ELISA.
- human VEGF165 protein was immobilized on a plate, and C1.02, C1.04, C1.05, and Aflibercept and hIgG 1 were bound as controls.
- an anti-human immunoglobulin G antibody and an anti mustard radish peroxidase (HRP) antibody were sequentially coupled.
- the fusion protein of one embodiment binds to C3b of the alternative pathway and inhibits the alternative pathway, but does not bind to human C2 or C4 protein of the classical pathway and thus does not inhibit the classical pathway.
- one specific method through an enzyme immunoassay method Binding of the example fusion protein C1.01 and human Cb3, C2 and C4 proteins was confirmed.
- human Cb3, C2 or C4 protein was immobilized on the plate and C1.02 was bound.
- the anti-human immunoglobulin G antibody and the anti mustard radish peroxidase (HRP) antibody were sequentially coupled.
- the hydrodynamic radius of the fusion protein according to the inclusion of the VEGF binder was analyzed by dynamic light scattering method.
- C1.01 and C1.02 were centrifuged at 12,000xg for 10 minutes, and the supernatant was added to a 96-well plate, followed by measurement at 25° C. using Zetasizer APS (Marlvern), a DLS analysis equipment.
- Table 14 below is a table showing the hydrodynamic radius of C1.01 and C1.02.
- FIGS. 9A and 9B It was confirmed that the fluid radius of C1.02 including the VEGF binder was measured longer than that of C1.01 without it.
- C1.02 viscosity In order to measure C1.02 viscosity by concentration, the viscosity of C1.02 of 33, 65 and 130 mg/ml was measured using micro-viscometer (m-VROC, RheoSence) and vROC-mB05 (RheoSence) chip. . In addition, the viscosity of 134 mg/ml of human serum albumin as a control was also measured.
- Table 16 below is a table showing the reagents used.
- hemolysis analysis of C1.01, C1.02, C1.04, C1.01m, C1.02m and C1.04m was performed.
- rabbit red blood cells were washed with TBS using a centrifuge at 400 x g for 10 min, and after repeating this process twice, the rabbit red blood cells were again centrifuged with GVB EGTA buffer at 400 x g for 10 min using a centrifuge. washed once. Next, the concentration of rabbit red blood cells was adjusted to 1 ⁇ 10 9 cells/mL using GVB EGTA buffer.
- C1.01, C1.02, C1.04, C1.01m, C1.02m and C1.04m were concentration-dependently hemolytic by the alternative complement pathway. was confirmed to inhibit.
- Table 17 below is a table showing the reagents used.
- C1.01, C1.02, C1.04, C1.05, C1.06, C1.01m, C1.02m, C1.04m Hemolysis assays (CH50) of , C1.06m, and C1.07m were performed.
- sheep red blood cells were centrifuged in TBS at 400xg for 10 minutes, and this process was repeated twice, and then incubated with 1 mL 20% sheep red blood cells and hemolysin at 4°C for 30 minutes.
- the sheep red blood cells were washed with TBS using a centrifuge at 400xg for 10 minutes, and this process was repeated twice, and then the sheep red blood cells were washed with GVB++ buffer using a centrifuge at 400xg for 10 minutes.
- the sensitized sheep red blood cells were adjusted to a concentration of 1x10 9 /mL using GVB++ buffer.
- VEGF signaling inhibitory effect was confirmed using a reporter cell. Specifically, afilibercept, C1.02, and C1.05 were activated using VEGF reporter cells (GA3001, Promega, USA) that generate luminescent light by receptor-mediated signaling when VEGF binds. Whether the binding to VEGF and VEGF receptors was inhibited was confirmed to the extent of luminescence.
- VEGF reporter cells G3001, Promega, USA
- the wound healing ability inhibitory effect of the fusion protein dimer was confirmed.
- VEGF signaling pathway inhibitory effect of C1.01, C1.02, and C1.05 was confirmed through a cell-based wound healing assay.
- ARPE-19 Adult Retinal Pigment Epithelial cell line-19
- ARPE-19 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)/F12 medium using 10% Fetal Bovine Serum (FBS).
- DMEM Dulbecco's Modified Eagle's Medium
- FBS Fetal Bovine Serum
- ARPE-19 cells (80,000 cells/well) were cultured overnight in a 24-well plate. The next day, after evenly wounding each well, VEGF (6 ng/ml) and C1.01, C1.02, and C1.05 (35 nM) were added to the culture medium, and 24 hours later, the wound healing inhibitory ability of each fusion protein was analyzed.
- the fusion protein dimer of one embodiment in the eye was confirmed by direct injection.
- mice In order to induce the choroidal neovascularization phenotype in mice, it was confirmed whether there were structural abnormalities in mice through pre-induction spectral region optical coherence tomography (Envisu R2200 SD-OCT System; Bioptigen, Inc., USA).
- choroidal neovascularizations were induced by penetrating Bruch's membrane in the right eye using a diode laser (OcuLight TX - Green 532nm Laser; Iridex Corporate, USA) (Day 0). After induction of choroidal neovascularization, it was confirmed whether the model was normally induced using spectral domain optical coherence tomography and fluorescence fundus angiography (HRA2 FA system; Heidelberg Engineering GmbH, Germany).
- C1.02m 350 ⁇ M; 48.3 ⁇ g/ ⁇ l, 2 ⁇ l
- apilibercept Esylea; 350 ⁇ M; 40.0 ⁇ g/ ⁇ l, 2 ⁇ l
- vehicle control 2 ⁇ l
- Intravitreal injection was injected intraocularly (Intravitreal injection). ) through the injection.
- In vivo imaging was performed immediately after induction of choroidal neovascularization (Day 0) and 7 days after induction (Day 7) using spectral domain optical coherence tomography and fluorescence fundus angiography. For each choroidal neovascularization, 1 point was given if there was a vascular leak and 0 if not, and the lesion probability was calculated after scoring. For example, a 100% notation means that vascular leakage is observed in three choroidal neovascularizations.
- the C1.02m group had a similar protective effect to the apilibercept group, and it was confirmed that there was a significant protective effect compared to the vehicle group.
- the fusion protein of one embodiment is directly injected into the eyeball Thus, the effect was confirmed.
- a wet macular degeneration rabbit model was prepared by inducing choroidal neovascularization in rabbits in a manner similar to the method described above in Experimental Example 10, except that 6 choroidal angiogenesis was induced. Immediately after induction of choroidal neovascularization, C1.01 (350 ⁇ M; 38.45 ⁇ g/ ⁇ l, 50 ⁇ l), Aflibercept (350 ⁇ M; 40 ⁇ g/ ⁇ l, 50 ⁇ l), or vehicle control (50 ⁇ l) was administered to the eye. Injected via my injection.
- In vivo imaging was performed immediately after induction of choroidal neovascularization (Day 0), 7 days after induction (Day 7), and 14 days after induction (Day 14) using a fluorescence fundus angiogram. Fluorescence intensity was measured in choroidal neovascularization to measure vascular leak.
- the C1.01 group had a similar protective effect to the apilibercept group, and it was confirmed that there was a significant protective effect compared to the vehicle group.
- the effect was confirmed by direct injection of the fusion protein of one embodiment into the eye after inducing choroidal neovascularization in a rat animal model.
- a wet macular degeneration rat model was prepared by inducing choroidal neovascularization in rats in a manner similar to the method described above in Experimental Example 10, except that 4 choroidal angiogenesis was induced.
- C1.02 350 ⁇ M; 54.93 ⁇ g/ ⁇ l, 5 ⁇ l
- apilibercept 350 ⁇ M; 40 ⁇ g/ ⁇ l, 5 ⁇ l
- vehicle control 5 ⁇ l
- in vivo imaging was performed using a fluorescence fundus angiogram and a spectral-domain optical coherence tomography machine. The presence or absence of choroidal neovascularization and the extent of vascular leak immediately after induction and 10 days after induction were quantified through imaging.
- the C1.02 group significantly reduced the number of choroidal neovascularization and the vascular leakage area, and had a similar protective effect as the afilibercept group, and significant protection compared to the vehicle group. It was confirmed that it was effective.
- the fusion protein of one embodiment is directly injected into the eye to confirm the effect did
- an animal model of dry macular degeneration was induced by administering 20 mg/kg sodium iodate (NaIO 3 ) to 8-week-old C57BL/6 mice via tail vein injection.
- C1.02m (260 ⁇ M; 36.1 ⁇ g/ ⁇ l, 1.5 ⁇ l) or vehicle control (1.5 ⁇ l) was administered on Day 0 and Day 7 via intraocular injection.
- test animals Two weeks after induction of the model, the test animals were euthanized, and their eyes were enucleated and fixed in Davidson's solution at 4°C for 24 hours. Next, the fixed samples were stored in 30% sucrose solution at 4°C for 3 days. After freezing the samples in OCT compound (Cat #4583, Sakura), they were cut to a thickness of 20 ⁇ m.
- the excised tissues were stained with C3 (Cat #MA1-40046, Thermofisher) protein using immunofluorescence and outer nuclear layer (ONL) by DAPI (Cat #H-1200, Vector Laboratories) staining. Stained samples were analyzed using a confocal microscope (LSM700; Zeiss, Germany). Specifically, the granular layer (ONL), the number of cells in the granular layer, the area of the granular layer, and the C3 expression level in the retina of each experimental group of the dry macular degeneration model were checked.
- FIGS. 19a to 19f it was confirmed that the C1.02m group significantly suppressed retinal degeneration compared to the vehicle group when the number and area of the extragranular layer were measured.
- the expression of C3 was significantly increased in the vehicle group compared to the non-AMD group, and it was confirmed that the expression of C3 was significantly decreased in the C1.02m group.
- 15 New Zealand white rabbits were divided into 5 groups (G01 to G05) with three per group. After grouping, 2,500 ⁇ g C1.02 (50 ⁇ l/eye) was administered via intraocular injection.
- 0.5 ml of blood was first collected intravenously from rabbits at each hour. Plasma was separated from the collected blood samples and stored frozen at -60°C. In addition, vitreous humor (0.2 ml) and aqueous humor (0.2 ml) were collected for each hour and stored frozen at -60°C.
- Table 18 below shows the collected rabbit samples by rabbit group, individual, and harvest time.
- Concentrations of C1.02 were determined in plasma, vitreous humor and aqueous humor using an enzyme immunoassay (ELISA). Pharmacokinetic parameters were obtained by performing non-compartmental pharmacokinetic analysis with the measured values. Table 19 below shows the pharmacokinetic parameters obtained by non-compartmental pharmacokinetic analysis.
- Matrix Aqueous humor Vitreous humor PK parameters Mean Mean C max (ng/mL) 103705 3204272 T max ( h) 1.00 1.00 T 1/2 ( h) 114 226 T last( h) 168 336 AUC 0-last (ng.h/mL) 10206790 545028800
- Table 20 below is a graph showing the concentration in the vitreous humor after administration of 2,500 ⁇ g of C1.02 via intraocular injection in rabbits; RB# means animal number, BQL means below the quantifiable limit, and ND means not determined.
- Table 21 below is a graph showing the concentration in the aqueous humor after administration of 2,500 ⁇ g of C1.02 via intraocular injection in rabbits; RB# means animal number, BQL means below the quantifiable limit, and ND means not determined.
- Table 22 below is a graph showing plasma concentrations after administration of 2,500 ⁇ g of C1.02 via intraocular injection in rabbits; RB# means animal number, BQL means below the quantifiable limit, and ND means not determined.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Code | Format | Description | 해당서열 |
C1.01 | Fc-fusion | hu CRIg-hu IgG1 Fc DANG | 서열번호 1 |
C1.02 | Fc-fusion | hu CRIg-hu IgG1 Fc-VEGF binder | 서열번호 2 |
C1.03 | Fc-fusion | hu IgG1 Fc DANG-hu CRIg | 서열번호 3 |
C1.04 | Fc-fusion | VEGF binder-hu IgG1 Fc DANG-hu CRIg | 서열번호 4 |
C1.05 | Fc-fusion | VEGF binder-hu IgG1 Fc DANG | 서열번호 5 |
C1.06 | Fc-fusion | hu IgG1 Fc DANG | 서열번호 6 |
C1.01m | Fc-fusion | mu CRIg-mu IgG2a Fc DANG | 서열번호 7 |
C1.02m | Fc-fusion | mu CRIg-mu IgG2a Fc DANG-VEGF binder | 서열번호 8 |
C1.03m | Fc-fusion | mu IgG2a Fc DANG-mu CRIg | 서열번호 9 |
C1.04m | Fc-fusion | VEGF binder-mu IgG2a Fc DANG-mu CRIg | 서열번호 10 |
C1.06m | Fc-fusion | mu IgG2a Fc DANG | 서열번호 11 |
C1.07m | Fc-fusion | mu IgG2a Fc DANG-VEGF binder | 서열번호 12 |
아필리버셉트 (Aflibercept) |
Fc-fusion | 아필리버셉트(Aflibercept) | 서열번호 13 |
시약 | 제조사 | Catalog# |
pTT5 | chempartner | |
In-Fusion HD cloning kit | Clontech | 639648 |
Accuprime pfx DNA polymerase | Invitrogen | 12344-04 |
Gel DNA fragment purication Kit | TaKaRa | D823A |
FastDigest® BamHI | Fermentas | FD0055 |
FastDigest® EcoRI | Fermentas | FD0275 |
장비 및 도구 | 제조사 | 모델명 |
생물 안전 작업대 | NUAIRE | LabGard class II |
원심분리기 | Eppendorf | 5424 |
젤 이미징 시스템 | Tanon | 2500R |
재료 및 시약 | 제조사(Product #) |
293F cells | Invitrogen(R790-07) |
OPM 293 | OPM(81075-001) |
Pluronic® F-68, 10%(100X) | Gibco(24040-032) |
1 mg/ml PEI | Polyscience(23966) |
OPTI MEM I | Gibco(31985088) |
Peptone(20x) | FLUKA(P0521-1KG) |
셰이커 플라스크 | |
ISF1-X 배양기 셰이커 | Kuhner shaker |
시약 | 제조사 | Catalog# |
Mabselect SuRe | GE Healthcare | 11003493 |
Tris | SIGMA | 77-86-1 |
NaCl | ACROS ORGANIVS | 7647-14-5 |
Sodium citrate | Adamas-beta | 76198B |
Citric acid | GENERAL-Reagent | G83162B |
Arginine | VETEC | V900343-500G |
Succinic acid | Sigma-Aldrich | S9512-500G |
Triton X-100 | ABCONE | X10010-1L |
TRITON X-114 | SIGMA-ALDRICH | X114 |
Millex-GP Filter Unit 0.22 μm Sterile | MILLIPORE | SLGP033RS |
NaOH | Merck | B146369740 |
용액 A | 25 mM Tris, 150 mM NaCl, pH 8.0 |
용액 B | 25 mM Tris, 150 mM NaCl,0.1% Triton X-100, 0.1% Triton X-114 pH 8.0 |
용액 C | 100 mM Sodium Citrate, 150 mM NaCl, pH 3.0 |
용액 D | 1 M Arginine, 400 mM Succinic acid, pH 9.0 |
용액 E | 20 mM PB pH 6.5, 1 M(NH4)2SO4 |
용액 F | 20 mM PB pH 6.5, 25% isopropyl alcohol |
최종용액 | 20 mM HEPES, pH 7.5, 240 mM sucrose 또는 20mM his acetate pH 5.5, 240 mM sucrose |
기기 | 제조사 | 모델명 |
AKTA Pure | GE Healthcare | 29-0182-24 |
원심분리기 | Beckman | J-26xp |
젤 이미징 시스템 | Tanon | 2500R |
Sartopore 2 filter | Sartorius | 5445307H9-OO-A |
재료 및 시약 | 제조사 | Cat. # |
Expi293FTM Cells | Gibco | A14527 |
Expi293TM Expression System Kit | Gibco | A14635 |
MabSelect SuRe | GE Lifesciences | 17543803 |
Superdex 200 increase 10/300 | GE Lifesciences | 28990944 |
MPCTM Ceramic Hydroxyfluoroapatite | Bio-rad | 1570200 |
재료 및 시약 | 제조사 | Cat. # |
NaCl | ACROS ORGANIVS | 7647-14-5 |
NaOH | Merck | B146369740 |
KH2PO4 | GENERAL-Reagent | 7778-77-0 |
NaH2PO4 | GENERAL-Reagent | 7558-80-7 |
EDTA | GENERAL-Reagent | 60-00-4 |
Benzamidine | Adamas | 618-39-3 |
PBS | Gibco | C10010500BT |
MgCl2 | GENERAL-Reagent | 7786-30-3 |
Factor B | Complement Technology | A135 |
Factor D | Complement Technology | A136 |
DEAE 컬럼 | |
용액 A | 10 mM Potassium phosphate(KH2PO4), 5 mM ethylenediaminetetraacetic acid disodium salt(EDTA), 1 mM benzamidine, pH 7.8 |
용액 B | 10 mM Potassium phosphate(KH2PO4), 5 mM EDTA, 1 mM benzamidine, 1 M sodium chloride(NaCl), pH 7.8 |
MonoS 컬럼 | |
용액A | 50 mM Sodium phosphate(NaH2PO4) |
용액B | 50 mM Sodium phosphate(NaH2PO4), 1 M sodium chloride(NaCl), pH 5.5 |
S200 컬럼 | |
용액 | Phosphate-buffered saline(PBS), pH 7.4 |
기기 | 제조사 | 모델명 |
AKTA Pure | GE Healthcare | 29-0182-24 |
원심분리기 | Beckman | J-26xp |
젤 이미징 시스템 | Tanon | 2500R |
Millex-GP Filter Unit 0.22 μm Sterile | MILLIPORE | SLGP033RS |
DEAE 16/10 FF | GE Healthcare | 10294207 |
Mono S 5/50 GL | GE Healthcare | 10298955 |
Sephadex S200 | GE Healthcare | 17104-302 |
HPLC | Waters | E2695 |
시약 | 제조사 | Cat # |
CM5 sensor chip | GE Healthcare | 29-1496-03 |
HBS-EP+ buffer(10 Υ) | GE Healthcare | BR-1006-69 |
Amine coupling kit | GE Healthcare | BR-1006-33 |
Human antibody Capture Kit | GE Healthcare | 29234600 |
10 mM Glycine 1.5 | GE Healthcare | BR-1003-54 |
C3b, C2 및 C4 | Complement Technology | A114, A112 및 A105 |
Capture 1 Solution | Analyte 1 Solution | ka(1/Ms) | kd(1/s) | KD(M) |
0.5 ug/ml C1.01 | C3b | 3.47E+06 | 1.21E-02 | 3.47E-09 |
2 ug/ml C1.02 | C3b | 3.66E+06 | 1.59E-02 | 4.34E-09 |
2 ug/ml C1.02 | human VEGF165 | 3.94E+06 | 2.47E-04 | 6.28E-11 |
C1.01 | C1.02 | ||
Z-Average(r.nm) | Test1 | 5.828 | 8.603 |
Test2 | 6.058 | 8.686 | |
Test3 | 6.078 | 8.596 | |
Mean | 5.988 | 8.628 |
시료(농도) | |||||
C1.02 (0 mg/ml) |
C1.02 (33 mg/ml) |
C1.02 (65 mg/ml) |
C1.02 (130 mg/ml) |
사람 혈청 알부민 (134 mg/ml) |
|
점도 (cP, mPa-s) |
1.235 | 1.851 | 3.327 | 13.912 | 2.194 |
Reagent | Vendor |
C1q-depleted serum | Comptech |
Rabbit RBC | Yuduo biolody |
Gelatin Veronal Buffer(5 mM Barbital) | Boston bioproducts |
Assay plate | Corning |
Reagent | 제조사 |
Factor B-Dpl serum | Comptech |
Sheep RBC | Yuduo biolody |
Hemolysin | Yuduo biolody |
Gelatin Veronal Buffer(GVB; 5 mM Barbital) | Boston bioproducts |
Assay plate | Corning |
Group | Animal Number | Dose Route | Sample and Tissue Collection Time Points(Days) | ||||
1 hr | 24 hr | 3 days | 7 days | 14 days | |||
G01 | RB1001, RB1002, RB1003 | Intravitreal injection | Vitreous humor, Aqueous humor, Plasma | ||||
G02 | RB2001, RB2002, RB2003 | Vitreous humor, Aqueous humor, Plasma | |||||
G03 | RB3001, RB3002, RB3003 | Vitreous humor, Aqueous humor, Plasma | |||||
G04 | RB4001, RB4002, RB4003 | Vitreous humor, Aqueous humor, Plasma | |||||
G05 | RB5001, RB5002, RB5003 | Vitreous humor, Aqueous humor, Plasma |
Matrix | Aqueous humor | Vitreous humor |
PK parameters | Mean | Mean |
Cmax(ng/mL) | 103705 | 3204272 |
Tmax(h) | 1.00 | 1.00 |
T1/2(h) | 114 | 226 |
Tlast(h) | 168 | 336 |
AUC0-last(ng.h/mL) | 10206790 | 545028800 |
Time(h) | RBn001* | RBn002 | RBn003 | Mean | SD | CV(%) | |
n=1 | 1 | 2789070 | 3594376 | 3229369 | 3204272 | 403239 | 12.6 |
n=2 | 24 | 1561470 | 1336610 | 2160474 | 1686185 | 425856 | 25.3 |
n=3 | 72 | 1638252 | 2031203 | 2506814 | 2058756 | 434936 | 21.1 |
n=4 | 168 | 1659880 | 1767054 | 1783308 | 1736747 | 67064 | 3.86 |
n=5 | 336 | 1206629 | 1286796 | 317153 | 936859 | 538176 | 57.4 |
Time(h) | RBn001* | RBn002 | RBn003 | Mean | SD | CV(%) | |
n=1 | 1 | 1542 | 4803 | 304769 | 103705 | 174135 | 168 |
n=2 | 24 | 84982 | 54751 | 85448 | 75061 | 17590 | 23.4 |
n=3 | 72 | 38192 | 78324 | 90493 | 69003 | 27368 | 39.7 |
n=4 | 168 | 30505 | 37937 | 29392 | 32612 | 4646 | 14.2 |
n=5 | 336 | BQL** | BQL | BQL | ND*** | ND | ND |
Time(h) | RBn001* | RBn002 | RBn003 | Mean | SD | CV(%) | |
n=1 | 1 | BQL** | BQL | BQL | ND*** | ND | ND |
n=2 | 24 | BQL | BQL | BQL | ND | ND | ND |
n=3 | 72 | BQL | BQL | BQL | ND | ND | ND |
n=4 | 168 | BQL | BQL | BQL | ND | ND | ND |
n=5 | 336 | BQL | BQL | BQL | ND | ND | ND |
Claims (25)
- CRIg(Complement receptor of the immunoglobulin superfamily)의 세포외도메인 또는 이의 단편; 및 VEGF(Vascular endothelial growth factor)에 특이적으로 결합하는 단백질을 포함하는 융합단백질.
- 제1항에 있어서,CRIg의 세포외도메인 또는 이의 단편; 및 VEGF에 특이적으로 결합하는 단백질은 링커에 의해 결합된 것인, 융합단백질.
- 제2항에 있어서,상기 링커는 펩타이드 링커, 면역글로불린 단편 또는 이의 조합인 것인, 융합단백질.
- 제3항에 있어서,상기 면역글로불린 단편은 DANG 변이 또는 NG 변이를 포함하는 것인, 융합단백질.
- 제3항에 있어서,상기 면역글로불린 단편은 서열번호 6, 서열번호 11 또는 서열번호 76의 아미노산 서열을 포함하는 것인, 융합단백질.
- 제1항에 있어서,상기 VEGF에 특이적으로 결합하는 단백질은 VEGF에 특이적으로 결합하는 항체 또는 이의 단편; VEGF 수용체의 세포외도메인을 포함하는 것인, 융합단백질.
- 제6항에 있어서,상기 VEGF 수용체는 VEGF 수용체 1 또는 VEGF 수용체 2인 것인, 융합단백질.
- 제7항에 있어서,상기 VEGF 수용체의 세포외도메인은 서열번호 14의 아미노산 서열을 포함하는 것인, 융합단백질.
- 제1항에 있어서,상기 융합단백질은 하기 구조식(I) 또는(II)로 이루어진 것인, 융합단백질:N'-X-[링커(1)]n-Fc 도메인-[링커(2)]m-Y-C'(I)N'-Y-[링커(1)]n-Fc 도메인-[링커(2)]m-X-C'(II)이때, 상기 구조식(I) 및 (II)에 있어서,상기 N'은 융합단백질의 N-말단이고,상기 C'는 융합단백질의 C-말단이며,상기 X는 CRIg의 세포외도메인 또는 이의 단편이고,상기 Y는 VEGF에 특이적으로 결합하는 단백질이며,상기 링커(1) 및 링커(2)는 펩타이드 링커이고,상기 n 및 m은 각각 독립적으로, O 또는 1이다.
- 제9항에 있어서,상기 링커(1)이 서열번호 15 또는 서열번호 17의 아미노산 서열을 포함하는 것인, 융합단백질.
- 제9항에 있어서,상기 링커(2)이 서열번호 16 또는 서열번호 18의 아미노산 서열을 포함하는 것인, 융합단백질.
- 제9항에 있어서,상기 융합단백질은 구조식(I)인, 융합단백질.
- 제1항에 있어서,상기 융합단백질은 서열번호 2, 서열번호 4, 서열번호 8 및 서열번호 10으로 이루어지는 군에서 선택된 어느 하나인, 융합단백질.
- 제1항 내지 제13항 중 어느 한 항의 융합단백질 2개가 결합된 융합단백질 이량체.
- 제14항에 있어서,상기 융합단백질 이량체는 동형이량체(Homodimer)인 것인, 융합단백질 이량체.
- 제1항 내지 제13항 중 어느 한 항의 융합단백질을 코딩하는 폴리뉴클레오티드.
- 제16항에 있어서,상기 폴리뉴클레오티드는 서열번호 24, 서열번호 26, 서열번호 30 및 서열번호 32로 이루어지는 군에서 선택된 어느 하나인 것인, 폴리뉴클레오티드.
- 제16항의 폴리뉴클레오티드를 포함하는 벡터.
- 제18항의 벡터가 도입된 형질전환 세포.
- 제1항의 융합단백질; 또는 제14항의 융합단백질 이량체를 유효성분으로 포함하는 안질환 치료 또는 예방용 약학 조성물.
- 제20항에 있어서,상기 안질환은 노화-관련 황반 변성(AMD), 지도모양 위축증(GA), 맥락막 혈관신생(CNV), 포도막염, 당뇨병성 및 다른 허혈-관련 망막증, 당뇨병성 황반 부종, 병리적 근시, 폰 힙펠-린다우병, 눈의 히스토플라스마증, 망막 중심 정맥 폐색(CRVO), 각막 혈관신생 및 망막 혈관신생으로 구성된 군에서 선택된 어느 하나인 것인, 안질환 치료 또는 예방용 약학 조성물.
- 제20항에 있어서,상기 약학 조성물은 약제학적으로 허용가능한 담체를 추가적으로 포함하는 것인, 안질환 치료 또는 예방용 약학 조성물.
- 안질환을 치료하기 위한 CRIg의 세포외도메인 또는 이의 단편; 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 또는 이의 이량체의 용도.
- 안질환 치료 또는 예방용 약제를 제조하기 위한 CRIg의 세포외도메인 또는 이의 단편; 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 또는 이의 이량체의 용도.
- CRIg의 세포외도메인 또는 이의 단편; 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 또는 이의 이량체를 개체에 투여하는 단계를 포함하는 안질환을 치료 및/또는 예방하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/004,613 US20230242633A1 (en) | 2020-07-07 | 2021-07-07 | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof |
CN202180053141.8A CN116234822A (zh) | 2020-07-07 | 2021-07-07 | 一种包括补体途径抑制剂和血管生成抑制剂的融合蛋白及其用途 |
AU2021304993A AU2021304993B2 (en) | 2020-07-07 | 2021-07-07 | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof |
CA3189030A CA3189030A1 (en) | 2020-07-07 | 2021-07-07 | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof |
EP21838564.9A EP4180453A4 (en) | 2020-07-07 | 2021-07-07 | FUSION PROTEIN WITH COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF |
JP2023501223A JP2023533038A (ja) | 2020-07-07 | 2021-07-07 | 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0083536 | 2020-07-07 | ||
KR20200083536 | 2020-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022010271A1 true WO2022010271A1 (ko) | 2022-01-13 |
Family
ID=79343023
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/008681 WO2022010271A1 (ko) | 2020-07-07 | 2021-07-07 | 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도 |
PCT/KR2021/008683 WO2022010273A1 (ko) | 2020-07-07 | 2021-07-07 | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/008683 WO2022010273A1 (ko) | 2020-07-07 | 2021-07-07 | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230242633A1 (ko) |
EP (1) | EP4180453A4 (ko) |
JP (1) | JP2023533038A (ko) |
KR (2) | KR20220006010A (ko) |
CN (1) | CN116234822A (ko) |
AU (1) | AU2021304993B2 (ko) |
CA (1) | CA3189030A1 (ko) |
TW (1) | TW202216755A (ko) |
WO (2) | WO2022010271A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024114641A1 (en) * | 2022-11-28 | 2024-06-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | C5/vegf bispecific binding molecules |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006042329A2 (en) * | 2004-10-12 | 2006-04-20 | Genentech, Inc. | Crig polypeptide for prevention and treatment of complement-associated disorders |
JP2007536964A (ja) | 2004-05-11 | 2007-12-20 | ライジョキ−プスカ、リトバ | 仮想風景を表示するための方法と装置 |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR20130130732A (ko) * | 2010-11-01 | 2013-12-02 | 제넨테크, 인크. | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 |
US20140294837A1 (en) * | 2013-03-28 | 2014-10-02 | Samsung Electronics Co., Ltd. | Fusion protein comprising anti-c-met antibody and vegf-binding fragment |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20180312819A1 (en) * | 2011-12-01 | 2018-11-01 | Ap Biosciences, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
US20190167790A1 (en) | 2017-12-05 | 2019-06-06 | Abbvie Biotherapeutics Inc. | Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers |
KR20190138636A (ko) * | 2017-03-22 | 2019-12-13 | 제넨테크, 인크. | 안구 장애의 치료를 위한 최적화된 항체 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
JP4897690B2 (ja) * | 2004-10-12 | 2012-03-14 | ジェネンテック, インコーポレイテッド | 補体関連障害の予防および処置のためのCRIgポリペプチド |
CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
US20190071477A1 (en) * | 2015-12-31 | 2019-03-07 | Quassia Biopharma Co., Ltd | Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof |
-
2021
- 2021-07-07 US US18/004,613 patent/US20230242633A1/en active Pending
- 2021-07-07 JP JP2023501223A patent/JP2023533038A/ja active Pending
- 2021-07-07 WO PCT/KR2021/008681 patent/WO2022010271A1/ko unknown
- 2021-07-07 CN CN202180053141.8A patent/CN116234822A/zh active Pending
- 2021-07-07 WO PCT/KR2021/008683 patent/WO2022010273A1/ko active Application Filing
- 2021-07-07 KR KR1020210089021A patent/KR20220006010A/ko unknown
- 2021-07-07 CA CA3189030A patent/CA3189030A1/en active Pending
- 2021-07-07 KR KR1020210089242A patent/KR20220006013A/ko unknown
- 2021-07-07 EP EP21838564.9A patent/EP4180453A4/en active Pending
- 2021-07-07 AU AU2021304993A patent/AU2021304993B2/en active Active
- 2021-07-07 TW TW110125019A patent/TW202216755A/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007536964A (ja) | 2004-05-11 | 2007-12-20 | ライジョキ−プスカ、リトバ | 仮想風景を表示するための方法と装置 |
WO2006042329A2 (en) * | 2004-10-12 | 2006-04-20 | Genentech, Inc. | Crig polypeptide for prevention and treatment of complement-associated disorders |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR20130130732A (ko) * | 2010-11-01 | 2013-12-02 | 제넨테크, 인크. | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20180312819A1 (en) * | 2011-12-01 | 2018-11-01 | Ap Biosciences, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
US20140294837A1 (en) * | 2013-03-28 | 2014-10-02 | Samsung Electronics Co., Ltd. | Fusion protein comprising anti-c-met antibody and vegf-binding fragment |
KR20190138636A (ko) * | 2017-03-22 | 2019-12-13 | 제넨테크, 인크. | 안구 장애의 치료를 위한 최적화된 항체 조성물 |
US20190167790A1 (en) | 2017-12-05 | 2019-06-06 | Abbvie Biotherapeutics Inc. | Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers |
Non-Patent Citations (2)
Title |
---|
"Remington's Pharmaceutical Sciences", 1995 |
See also references of EP4180453A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024114641A1 (en) * | 2022-11-28 | 2024-06-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | C5/vegf bispecific binding molecules |
Also Published As
Publication number | Publication date |
---|---|
CN116234822A (zh) | 2023-06-06 |
CA3189030A1 (en) | 2022-01-13 |
EP4180453A4 (en) | 2023-12-27 |
KR20220006010A (ko) | 2022-01-14 |
KR20220006013A (ko) | 2022-01-14 |
AU2021304993B2 (en) | 2024-05-09 |
JP2023533038A (ja) | 2023-08-01 |
AU2021304993A1 (en) | 2023-02-23 |
WO2022010273A1 (ko) | 2022-01-13 |
EP4180453A1 (en) | 2023-05-17 |
US20230242633A1 (en) | 2023-08-03 |
TW202216755A (zh) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020060122A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 | |
WO2019225787A1 (ko) | 항-b7-h3 항체 및 그 용도 | |
WO2015058573A1 (zh) | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 | |
WO2019004799A1 (ko) | Vegf-grab 단백질과 약물의 결합체 및 이의 용도 | |
WO2014090053A1 (zh) | 拮抗抑制血管内皮细胞生长因子与其受体结合的单克隆抗体及其编码序列与用途 | |
WO2016137108A1 (en) | Novel antibody binding to tfpi and composition comprising the same | |
WO2012165925A2 (ko) | Hgf 활성을 가지는 c-met에 대한 인간항체 및 이의 용도 | |
WO2019164219A1 (en) | Anti-angiopoietin-2 antibodies and uses thereof | |
WO2021071319A1 (ko) | 다중 특이적 융합 단백질 및 이의 용도 | |
WO2022010271A1 (ko) | 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도 | |
EP3755714A1 (en) | Anti-angiopoietin-2 antibodies and uses thereof | |
WO2020101365A1 (ko) | 안정성이 향상된 항 c-met 항체 또는 그의 항원 결합 단편 | |
WO2019045477A1 (ko) | 비멘틴 유래 펩타이드에 특이적으로 결합하는 물질을 포함하는 피부질환 예방 및 치료용 조성물 | |
WO2022035200A1 (ko) | Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2019132579A2 (ko) | 세포질 침투 항체에 융합된 rna 분해효소를 포함하는 면역독소 | |
WO2019235856A1 (ko) | Tie2에 결합하는 항체 및 이의 용도 | |
WO2023132547A1 (ko) | 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도 | |
WO2022235140A1 (ko) | 단일사슬항체조각 및 페리틴의 융합단백질을 포함하는 나노입자 및 이의 용도 | |
WO2023224429A1 (ko) | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2020138868A1 (ko) | 타입 1 인터페론 중화 fc-융합 단백질 및 이의 용도 | |
WO2022045865A1 (ko) | 항-vegf 육량체 항체, 및 이를 포함하는 조성물 | |
WO2019088658A1 (ko) | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 | |
WO2022169269A1 (ko) | 항 ctla-4 항체 및 이의 용도 | |
WO2023048516A1 (ko) | Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도 | |
WO2023249425A1 (ko) | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21838564 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023501223 Country of ref document: JP Kind code of ref document: A Ref document number: 3189030 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021838564 Country of ref document: EP Effective date: 20230207 |
|
ENP | Entry into the national phase |
Ref document number: 2021304993 Country of ref document: AU Date of ref document: 20210707 Kind code of ref document: A |